CG-0988 

CG-0988 is a selective SARS-CoV-2 3C-like protease (3CL^pro) inhibitor with an IC₅₀ of 8.5 nM. CG-0988 functionally inhibits SARS-CoV-2 3CL^pro, blocks SARS-CoV-2 replication, and exerts antiviral activity against SARS-CoV-2 variants. CG-0988 can be used in research related to coronavirus disease 2019 (COVID-19)^[1].

CG-0988 (4.6-10000 nM; 24 h) potently inhibits SARS-CoV-2 replication in replicon-transfected Huh7 cells, with an EC₅₀ of 6.6 nM^[1].
CG-0988 (1 μM; 3 days) potently inhibits infection of Vero E6 cells by SARS-CoV-2 USA_WA1/2020, Delta B.1.617.2 and Omicron EG.5.1 variants, with EC₅₀ values of < 1, 2 and 4 nM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CG-0988 (10 mg/kg; p.o.; single dose) exhibits favorable oral pharmacokinetic properties in male Sprague-Dawley rats, with 59.2% oral bioavailability and longer plasma half-life than nirmatrelvir^[1].
CG-0988 (1-3 mg/kg; i.v., p.o.; single dose) exhibits excellent oral pharmacokinetic properties in beagle dogs, with 94.0% oral bioavailability and slow plasma clearance^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

529.56

C₂₉H₂₈FN₅O₄

3069291-10-4

O=C(C1CC1)C2=CC3=C(N2)C(N([C@@H](CC(F)(C)C)C(N4C[C@]5(C[C@H]4C#N)C(NC6=C5C=CC=C6)=O)=O)C=C3)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Tang X, et al. Discovery of preclinical candidate CG-0988, a novel severe acute respiratory syndrome coronavirus 2 3CL protease inhibitor bearing spirooxindole. Eur J Med Chem. 2026 Sep 15;314:118889.